Circio Holding ASA (OSL:CRNA)
Norway · Delayed Price · Currency is NOK | Market Cap | 2.79B +3,986.5% |
| Revenue (ttm) | n/a |
| Net Income | -45.91M |
| EPS | -0.44 |
| Shares Out | 238.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,078,377 |
| Average Volume | 16,880,112 |
| Open | 11.60 |
| Previous Close | 11.20 |
| Day's Range | 11.46 - 12.28 |
| 52-Week Range | 0.55 - 14.46 |
| Beta | -1.22 |
| RSI | 66.39 |
| Earnings Date | Apr 15, 2026 |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec. The company has a research collaboration with United Immunity Co., Ltd. for the dev... [Read more]
Financial Performance
Financial StatementsNews
Circio Holding ASA Transcript: R&D update
circVec technology shows robust, reproducible, and highly potent gene expression in heart and eye, with significant dose-sparing and safety advantages. The platform is advancing disease-specific constructs and in vivo CAR applications, supported by strong fundraising and ongoing collaborations.
Circio Holding ASA Transcript: R&D Update
circVec technology delivers significantly higher and more durable protein expression than conventional approaches, with strong preclinical results in heart, eye, and CNS models. Lead programs are advancing toward key efficacy milestones, supported by new pharma collaborations and a robust financial position.
Circio Holding ASA Earnings Call Transcript: Q2 2025
Strong R&D progress with circVec platform led to up to 44x improved heart expression and 15x in eye, while financial stability was secured through extended Atlas financing. Seven new collaborations and a lean cost structure position the company for further growth and new partnerships.
Circio Holding ASA Transcript: R&D Update
Circular RNA technology is advancing rapidly, with circVec showing strong potential to enhance gene therapy efficacy and safety, especially in muscle, heart, and spleen tissues. Multiple collaborations and secured financing support ongoing R&D and business development, with key milestones ahead.
Circio Holding ASA Transcript: R&D Update
Significant R&D progress includes a 27x improvement with circVec 3.0, successful in vivo delivery to spleen, and up to 50% higher protein expression in AAV vectors. Financially, the company secured NOK 30 million, reduced costs, and extended its financing runway. Key data readouts and potential partnerships are expected in the coming months.
Circio Holding ASA Transcript: R&D Update
CircVec 3.0 delivers a major leap in circular mRNA technology, offering up to 27 times higher protein expression and up to 75 times longer half-life than mRNA. The platform is advancing toward gene therapy applications, with muscular dystrophies as initial targets and clinical entry expected within three years.
Circio Holding ASA Earnings Call Transcript: Q2 2024
circVec technology demonstrated superior durability and expression over mRNA, with ongoing upgrades and five new research collaborations. Financial position improved by a NOK 70 million loan waiver and a successful rights issue, securing funding until mid-2025.